Oxford Biodynamics (OBD) has partnered with King's College London to leverage the EpiSwitch technology in rheumatoid arthritis (RA) treatment, following a successful APIPPRA trial for Abatacept, a biological therapy used to treat arthritis by targeting the cause of inflammation.

Using OBD’s proprietary EpiSwitch platform, the collaboration aims to identify patients at high risk of having RA who can benefit from the therapeutics of Abatacept. EpiSwitch is an epigenetic platform that can identify and validate biomarkers for various diseases, including cancer and autoimmune and neurodegenerative conditions. The APIPPRA trial had reportedly shown positive results, with 92.8% of patients who received Abatacept therapy remaining RA-free after a year. 

Oxford BioDynamics is a UK-based biotechnology company that develops precision medicine tests through its proprietary EpiSwitch 3D genomics platform. This platform allows the creation of molecular diagnostic classifiers for a range of applications, including drug response prediction, diagnosis, and patient prognosis. OBD’s key products include EpiSwitch CiRT (Checkpoint Inhibitor Response Test) for predicting cancer immunotherapy responses, EpiSwitch PSE (Prostate Screening Test), EpiSwitch CST (Covid Severity Test), and EpiSwitch Explorer for 3D genome profiling.